Back to news

IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors

PR Newswire•15/11/2026•15:00 ET
20

Key Highlights

  • ➤IDE101 nominated as IDEAYA’s next development candidate targeting CDKN2A-deficient solid tumors
  • ➤CDKN2A-deficiency affects approximately 10-15% of solid tumors and ~70% of pancreatic cancer
  • ➤IND-enabling studies underway, supporting planned FDA IND filing in H1 2027
  • ➤IDE101 showed encouraging preclinical activity alone and with RAS, MTAP, and PRMT5 inhibitors

Expert Statements

Michael White, President of Research and Development at IDEAYA Biosciences

“We are excited to announce the nomination of IDE101 as our next development candidate in our precision medicine pipeline. IDE101 is a novel, first-in-class molecule that targets the key drivers of tumorigenesis resulting from CDKN2A-deficiency. We plan to focus development of IDE101 in tumors with a high frequency of CDKN2A-deficiency, including as a monotherapy agent and in combination with RAS inhibitors for pancreatic cancer and in combination with IDE892, our proprietary PRMT5 inhibitor, in MTAP-deleted solid tumors. We believe there is strong potential to drive better efficacy in these cancers by co-targeting tumor suppressor loss with IDE101 and key driver oncogene dependencies, such as KRAS, through rational combinations.”

Michael White, President of Research and Development at IDEAYA Biosciences

“We are pushing ahead with urgency to complete the IND-enabling work necessary to support an IND filing in the first half of next year.”

IDEAYA Biosciences Announces Development Candidate Nomination of IDE101, a Potential First-In-Class Inhibitor Targeting CDKN2A-Deficiency in Solid Tumors PR Newswire

* Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combination with inhibitors of RAS and MTAP, including IDEAYA's proprietary Phase 1 PRMT5 inhibitor IDE892 * CDKN2A-deficiency is a common tumor suppressor loss prevalent in ~10-15% of all solid tumors, including ~70% of pancreatic cancer * IDE101's preclinical profile, including combination results with inhibitors of PRMT5 and pan-RAS, will be summarized at IDEAYA's London R&D Day * IND-enabling studies underway to support an IND filing in H1 2027 SOUTH SAN FRANCISCO, Calif., Nov. 15, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced development candidate nomination of IDE101, a potential first-in-class dual cyclin-dependent kinase (CDK) inhibitor designed to address the loss of CDKN2A-mediated tumor suppressor function in cancer. CDKN2A-deficiency occurs in approximately 10-15% of all solid tumors, including ~70% of pancreatic ductal adenocarcinoma (PDAC), and is typically co-deleted in methylthioadenosine phosphorylase (MTAP)-deficient cancers given their proximity on chromosome 9p21.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in